Score Breakdown
Offering Ability
42
Cash Runway
95
Float Risk
40
Warrant Exposure
15
Convertible Debt
40
Dilution Forecast
🌥️
Advisory
Moderate dilution signals present
model est. 43%
💰 Capital Raise
model 55%
• Critical: only 0.3 months cash remaining
🔄 Reverse Split
model est. 45%
• 50-day avg $1.40 approaching $1 threshold
• Only 0 months cash — financial pressure
📉 Score Deterioration
model 10%
• Score in HIGH risk zone (65/100)
Market Data
Market Cap$28.25M
Shares Outstanding20.18M
Float11.52M
Cash$20.0K
Debt$41.0K
Short InterestN/A
Institutional Holdings
Institutional data not yet available.
Short Interest
No current FINRA short-interest record is available for this ticker.
Recent SEC Activity
xbrl
XBRL CONVERTIBLE
2025-12-31
xbrl
XBRL WARRANT
2025-12-31
Full SEC filing analysis available with free account →
Recent News
No recent news
Factual RAPH Dilution Snapshot
Raphael Pharmaceutical Inc. (RAPH) has a DilutionScore of 65/100, rated High dilution risk. Score date: August 28, 2026.
- Stored outstanding warrants: 1.0M.
- Recent SEC activity tracked for RAPH: xbrl on 2025-12-31; xbrl on 2025-12-31.
This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.
Related Stocks — HIGH Risk
Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles: